Monitor NBP's next periodic filing (20-F or 6-K) for Deloitte's audit opinion and any updates on remediation of ITGC material weaknesses. The lack of disagreements is reassuring, but the recurrence of material weaknesses in two consecutive years could lead to further scrutiny or a qualified opinion if not resolved.
Price Chart
Executive Summary
NovaBridge Biosciences dismissed its auditor PwC and appointed Deloitte as its new independent registered public accounting firm, effective immediately. The change was approved by the Audit Committee and comes with no reported disagreements, though material weaknesses in ITGCs existed in prior years and were previously disclosed. This is a routine auditor transition for a foreign private issuer, but the persistence of material weaknesses warrants monitoring.
Key Facts
- PwC dismissed as independent auditor effective June 16, 2026; no adverse or qualified opinions on FY2024 and FY2025 financial statements.
- No disagreements on accounting principles or audit scope occurred during FY2024, FY2025, or through June 16, 2026.
- Reportable events were limited to previously disclosed material weaknesses in ineffective information technology general controls (ITGCs) as of December 31, 2024 and 2025.
- Deloitte Touche Tohmatsu Certified Public Accountants LLP appointed as new auditor for fiscal year ending December 31, 2026.
- No prior consultations with Deloitte regarding accounting principles or audit opinions occurred.
Financial Impact
No financial impact disclosed; auditor change may affect audit costs but terms were not disclosed.
Risk Factors
- Potential for future disagreements with new auditor if unresolved material weaknesses escalate.
- Auditor change may raise perception of accounting risk, potentially increasing cost of capital.
- ITGC material weaknesses could lead to financial reporting delays or restatements if not remediated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001778016-26-000005 |
| Document: nbp-ex16_1.htm | 0001778016-26-000005 |
| Document: 0001778016-26-000005-index-headers.html | 0001778016-26-000005 |
| Document: 0001778016-26-000005-index.html | 0001778016-26-000005 |
| Document: 0001778016-26-000005.txt | 0001778016-26-000005 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.49 | awaiting T+5 | — | $1.22 (−18.46%) |
Oct 25, 2026 1d ago | Press Release | $1.42 | awaiting T+5 | — | $1.22 (−14.44%) |
Oct 23, 2026 3d ago | 6-K | $1.37 | awaiting T+5 | — | $1.22 (−11.31%) |
Oct 13, 2026 13d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.22 (−5.81%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.22 (−36.39%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.22 (−31.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers